Title:
METHODS AND COMPOSITIONS INVOLVING INTERLEUKIN-6 RECEPTOR ALPHA-BINDING SINGLE CHAIN VARIABLE FRAGMENTS
Document Type and Number:
WIPO Patent Application WO/2018/042385
Kind Code:
A3
Abstract:
Disclosed are compositions comprising an isolated chimeric interleukin 6 receptor alpha (IL-6Rα) binding protein or cells expressing an isolated chimeric IL-6Rα binding protein. The isolated IL-6Rα chimeric binding protein and cells expressing the protein may be used in methods of treating cancer and reducing the risk of cytokine release syndrome.
Inventors:
CHEN YVONNE YU-HSUAN (US)
LIN MENG-YIN (US)
LIN MENG-YIN (US)
Application Number:
PCT/IB2017/055281
Publication Date:
April 19, 2018
Filing Date:
September 01, 2017
Export Citation:
Assignee:
UNIV CALIFORNIA (US)
International Classes:
A61K39/395; A61K51/10; C07K14/705; C07K16/28
Domestic Patent References:
| WO2006046661A1 | 2006-05-04 | |||
| WO1994012520A1 | 1994-06-09 | |||
| WO2011140170A1 | 2011-11-10 |
Other References:
MAUDE ET AL.: "Managing Cytokine Release Syndrome Associated With Novel T Cell -Engaging Therapies", CANCER J., vol. 20, no. 2, March 2014 (2014-03-01), pages 119 - 122, XP055188104
CHMIELEWSKI ET AL.: "IL -12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression", CANCER RES., vol. 71, no. 17, 1 September 2011 (2011-09-01), pages 5697 - 706, XP055185302
CHMIELEWSKI ET AL.: "IL -12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression", CANCER RES., vol. 71, no. 17, 1 September 2011 (2011-09-01), pages 5697 - 706, XP055185302
Attorney, Agent or Firm:
STELLMAN, Laurie et al. (US)
Download PDF: